Top Markets
Coin of the day
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Rank in Stocks #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Share Price
$14.66
Last synced: 2026-08-28
Market Cap
$839.37M
Change (1 day)
-2.67%
Change (1 year)
557.32%
Country
US
Trade Climb Bio, Inc. (CLYM)

Category

EPS for Climb Bio, Inc. (CLYM)
EPS as of 2026 TTM: 0
According to Climb Bio, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Climb Bio, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH